1.270NOK-0.78%Mkt Cap: 143.89M NOKP/E: —Last update: 2026-05-13
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an ap…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B2.66
P/S2438.84
EV/EBITDA-0.70
EV/Revenue977.93
EPS (TTM)-1.37
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-38.70%
FCF Margin-94387.52%
Operating CF-66.99M NOK
CapEx (TTM)5.32M NOK
Net Debt/EBITDA0.29
Net Debt-23.91M NOK
Technical
SMA 501.698 (-25.2%)
SMA 2001.904 (-33.3%)
Beta0.14
S&P 52W Chg24.23%
Avg Vol (30d)94.19K
Avg Vol (10d)102.92K
Technical Indicators
RSI (14)31.5
MACD-0.1123
MACD Signal-0.1077
MACD Hist.-0.0046
BB Upper1.633 NOK
BB Middle1.444 NOK
BB Lower1.255 NOK
BB Width26.19%
ATR (14)0.0966 NOK
Vol Ratio (20d)3.46x
52W Range
1.1506% of range3.280
52W High3.280 NOK
52W Low1.150 NOK
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-66142.46%
ROE-283.21%
ROA-129.04%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.01
Current Ratio1.65
Quick Ratio0.85
Book Value/Sh0.4850 NOK
Cash/Share0.3850 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split250:1
Split DateJul 27, 2020
Ownership
Shares Out.111.54M
Float16.23M
Insiders33.68%
Institutions12.54%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap143.89M NOK
Enterprise Value57.70M NOK
Revenue (TTM)59.00K NOK
Gross Profit59.00K NOK
Net Income (TTM)-86.97M NOK
Revenue/Share0.0010 NOK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees11
Last Price1.270 NOK
CountryNO
SectorHealthcare
IndustryBiotechnology
ISIN—